{"id":"dronabinol-in-oral-dosage-form","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Euphoria"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dronabinol (delta-9-tetrahydrocannabinol, THC) binds to and activates cannabinoid receptors in the central and peripheral nervous systems. This activation influences appetite regulation, nausea/vomiting pathways, and potentially anti-inflammatory and immunomodulatory processes. The exact mechanisms in oncology contexts may involve appetite stimulation, symptom management, and potential direct anti-tumor effects under investigation.","oneSentence":"Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:01.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer-related anorexia and cachexia (Phase 3 investigation)"},{"name":"Chemotherapy-induced nausea and vomiting (potential indication)"}]},"trialDetails":[{"nctId":"NCT04734080","phase":"PHASE4","title":"Dronabinol in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-03-09","conditions":"Total Knee Arthroplasty, Opioid Use","enrollment":114},{"nctId":"NCT06533657","phase":"PHASE2","title":"Unique Treatment of Oncology Pain in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ZYUS Life Sciences Inc.","startDate":"2025-06-12","conditions":"Cancer Pain","enrollment":20},{"nctId":"NCT06891235","phase":"","title":"Study of Oral Fluid Testing Approach","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-10-27","conditions":"Cannabis Use, Cannabis Intoxication, Cannabis Use Disorder","enrollment":200},{"nctId":"NCT07459920","phase":"PHASE2","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2026-04-01","conditions":"Advanced Malignant Solid Tumor","enrollment":156},{"nctId":"NCT05067387","phase":"PHASE1","title":"Evaluation of Oral THC and CBD in Men and Women","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-04-15","conditions":"Drug Abuse, Intoxication by Drug, Impairment","enrollment":22},{"nctId":"NCT07422311","phase":"PHASE2, PHASE3","title":"To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Benuvia Therapeutics Inc.","startDate":"2026-05-01","conditions":"Agitation in Dementia","enrollment":140},{"nctId":"NCT05906511","phase":"EARLY_PHASE1","title":"PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-10-17","conditions":"Pain, Tolerance, Oral vs Vaporized THC, Abuse Liability","enrollment":20},{"nctId":"NCT06772753","phase":"PHASE1","title":"Investigation of Psychedelic Effects in Psychoactive Substances","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-02-05","conditions":"Psychedelic Effects in Healthy Volunteers","enrollment":50},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT07225777","phase":"PHASE2","title":"Sex Differences in Neurobehavioral Response to THC","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-04-01","conditions":"Cannabis Use Disorder","enrollment":40},{"nctId":"NCT03560934","phase":"EARLY_PHASE1","title":"Tetrahydrocannabinol (THC) and Sleep","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-09-01","conditions":"Sleep, THC, Marijuana","enrollment":18},{"nctId":"NCT05052541","phase":"PHASE3","title":"Safety and Efficacy of Oral Cannabis in Chronic Spine Pain","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01","conditions":"Back Pain, Neck Pain","enrollment":157},{"nctId":"NCT05543681","phase":"PHASE2","title":"Clinical Trial on Agitation in Alzheimer's Dementia","status":"RECRUITING","sponsor":"IGC Pharma, LLC","startDate":"2022-10-11","conditions":"Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden","enrollment":164},{"nctId":"NCT06878417","phase":"NA","title":"Cannabinoids for Osteoarthritis Pain Effectiveness Trial","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-01-15","conditions":"Osteoarthritis of Knee, Osteoarthritis Hip","enrollment":100},{"nctId":"NCT07176208","phase":"PHASE1","title":"Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults","status":"RECRUITING","sponsor":"Food and Drug Administration (FDA)","startDate":"2025-12-29","conditions":"Cannabis, Drug Effects, Driving Performance","enrollment":48},{"nctId":"NCT05351905","phase":"NA","title":"Improving Pain Disability With the Use of Oral Cannabinoids","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-11-22","conditions":"Chronic Pain, Opioid Use, Cannabis","enrollment":51},{"nctId":"NCT05644262","phase":"PHASE2","title":"Life's End Benefits of cannaBidiol and tetrahYdrocannabinol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-12-18","conditions":"Agitation, Dementia","enrollment":120},{"nctId":"NCT07199218","phase":"PHASE2","title":"Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism","status":"RECRUITING","sponsor":"Bazelet Nehushtan LtD.","startDate":"2025-10-05","conditions":"Autism, Autism Spectrum Disorder","enrollment":78},{"nctId":"NCT06034314","phase":"PHASE1","title":"Oral Dronabinol-HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2023-09-21","conditions":"HIV","enrollment":160},{"nctId":"NCT05519111","phase":"PHASE2","title":"Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-04-03","conditions":"Sickle Cell Disease","enrollment":60},{"nctId":"NCT02069366","phase":"NA","title":"Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2014-11","conditions":"Post-Traumatic Stress Disorder","enrollment":86},{"nctId":"NCT07146945","phase":"PHASE1","title":"A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Delphian Therapeutics Australia Pty, Ltd","startDate":"2025-08-30","conditions":"Healthy Participants","enrollment":84},{"nctId":"NCT03008005","phase":"PHASE4","title":"Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2017-06-01","conditions":"PostTraumatic Stress Disorder","enrollment":46},{"nctId":"NCT04448808","phase":"PHASE2","title":"Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-10-01","conditions":"Posttraumatic Stress Disorder","enrollment":170},{"nctId":"NCT05269628","phase":"PHASE2","title":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","status":"RECRUITING","sponsor":"Tiffany J. Braley, MD, MS","startDate":"2022-03-25","conditions":"Multiple Sclerosis, Sleep, Pain","enrollment":166},{"nctId":"NCT04080427","phase":"PHASE1","title":"Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2021-04-15","conditions":"Posttraumatic Stress Disorder","enrollment":102},{"nctId":"NCT06601218","phase":"PHASE1","title":"Impact of Daily Oral Cannabis Doses in Patients With Cancer","status":"RECRUITING","sponsor":"Shanna Babalonis, PhD","startDate":"2025-06-17","conditions":"Cancer, Cancers, Pain","enrollment":80},{"nctId":"NCT04512365","phase":"EARLY_PHASE1","title":"Reward and Drug Effects on Mood and Brain Response","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2021-03-16","conditions":"Cannabis Use, Healthy","enrollment":141},{"nctId":"NCT06378957","phase":"PHASE1","title":"Behavioral Pharmacology of Orally Administered THC and D-limonene","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-02-14","conditions":"Subjective Drug Effects, THC, D-limonene","enrollment":65},{"nctId":"NCT04596826","phase":"PHASE2","title":"The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary Open Angle Glaucoma","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-11-11","conditions":"Retinal Blood Flow","enrollment":51},{"nctId":"NCT05126888","phase":"PHASE2","title":"SCI-110 in the Treatment of Tourette Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Neurothera Labs Inc.","startDate":"2025-08","conditions":"Tourette Syndrome","enrollment":164},{"nctId":"NCT02709954","phase":"PHASE1","title":"Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2016-03","conditions":"Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs","enrollment":40},{"nctId":"NCT03984214","phase":"PHASE3","title":"Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-12-16","conditions":"Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic","enrollment":109},{"nctId":"NCT03825965","phase":"PHASE3","title":"Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT","status":"COMPLETED","sponsor":"McMaster University","startDate":"2023-05-03","conditions":"Knee Osteoarthritis","enrollment":39},{"nctId":"NCT04989413","phase":"PHASE2, PHASE3","title":"Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -","status":"TERMINATED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-10-18","conditions":"Chronic Migraine, Headache, Overuse Headache Medication","enrollment":110},{"nctId":"NCT05514899","phase":"PHASE2","title":"Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-09-01","conditions":"HIV, Cannabis, THC","enrollment":90},{"nctId":"NCT05478863","phase":"EARLY_PHASE1","title":"The Pharmacodynamics of Cannabinoid-Caffeine Combinations","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2023-01-20","conditions":"Behavioral Pharmacology of Cannabinoids","enrollment":20},{"nctId":"NCT04231643","phase":"EARLY_PHASE1","title":"Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2021-09-01","conditions":"Bipolar Disorder","enrollment":19},{"nctId":"NCT02901275","phase":"PHASE2","title":"Enhancing Medication-based Analgesia in Humans","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-12","conditions":"Pain, Cannabis, Opioid Use, Unspecified","enrollment":29},{"nctId":"NCT02460692","phase":"PHASE2","title":"Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-12","conditions":"Cannabis, Low Back Pain, Neuropathic Pain","enrollment":131},{"nctId":"NCT04605393","phase":"NA","title":"Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-01-01","conditions":"Schizophrenia, Cannabis Use","enrollment":36},{"nctId":"NCT04820361","phase":"NA","title":"Effect of Cannabinoids on Pain in Fabry Disease Patients","status":"UNKNOWN","sponsor":"Albina Nowak, MD","startDate":"2022-07-07","conditions":"Pain, Neuropathic","enrollment":22},{"nctId":"NCT05101122","phase":"PHASE1, PHASE2","title":"Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-10-19","conditions":"Obstructive Sleep Apnea","enrollment":15},{"nctId":"NCT05272865","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC","status":"UNKNOWN","sponsor":"LaSanta S A S","startDate":"2023-08-15","conditions":"Nausea Post Chemotherapy, Vomiting, Cancer Pain","enrollment":334},{"nctId":"NCT01964547","phase":"PHASE4","title":"A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2012-01","conditions":"Multiple Sclerosis, Spasticity","enrollment":121},{"nctId":"NCT01887301","phase":"PHASE1","title":"Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-07","conditions":"Hepatic Impairment","enrollment":32},{"nctId":"NCT01898520","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-12","conditions":"Cerebral Palsy","enrollment":72},{"nctId":"NCT04261166","phase":"PHASE1","title":"A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract","status":"COMPLETED","sponsor":"Breath of Life International Pharma Ltd","startDate":"2019-07-24","conditions":"Healthy","enrollment":76},{"nctId":"NCT04930796","phase":"PHASE1","title":"Food Effect Study of VER-01 in Healthy Volunteers","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2022-08-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT03655717","phase":"NA","title":"Using Imaging to Assess Effects of THC on Brain Activity","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-05","conditions":"Intoxication Alcohol, Intoxication THC, Intoxication Combined Alcohol THC","enrollment":316},{"nctId":"NCT04930809","phase":"PHASE1","title":"Single and Multiple Dose Study of VER-01 in Healthy Volunteers","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2021-11-25","conditions":"Healthy","enrollment":42},{"nctId":"NCT03550352","phase":"PHASE2","title":"Cannabinoids in PLWHIV on Effective ART","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-08-20","conditions":"HIV Infections","enrollment":10},{"nctId":"NCT05002946","phase":"PHASE1","title":"Pharmacokinetics of SP-104","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT04958876","phase":"PHASE1","title":"Study to Evaluate the Safety of SP-104","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2021-10-04","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT02983695","phase":"PHASE1","title":"Cannabinoid Therapy for Pediatric Epilepsy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2017-02-02","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT03756974","phase":"PHASE3","title":"BX-1 in Spasticity Due to Multiple Sclerosis","status":"COMPLETED","sponsor":"Bionorica SE","startDate":"2019-02-18","conditions":"Spasticity Due to Multiple Sclerosis","enrollment":397},{"nctId":"NCT04601207","phase":"PHASE1","title":"A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population","status":"COMPLETED","sponsor":"New Age Ventures LLC","startDate":"2020-06-19","conditions":"Healthy, Cannabis","enrollment":32},{"nctId":"NCT00553059","phase":"PHASE3","title":"Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":62},{"nctId":"NCT03106363","phase":"EARLY_PHASE1","title":"Combined Alcohol and Cannabis Effects on Skills of Young Drivers","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2017-07-04","conditions":"Psychomotor Impairment","enrollment":85},{"nctId":"NCT03164512","phase":"PHASE1","title":"The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Cannabidiol Pharmacokinetics","enrollment":19},{"nctId":"NCT03246113","phase":"PHASE1","title":"Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-03-19","conditions":"Glioblastoma","enrollment":1},{"nctId":"NCT03471585","phase":"EARLY_PHASE1","title":"Effects of THC on Emotional Memory Retrieval","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-02-15","conditions":"Healthy","enrollment":24},{"nctId":"NCT02956226","phase":"PHASE2","title":"Cannabinoids for Behavioral Problems in Children With ASD","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2017-01","conditions":"Autistic Disorder","enrollment":150},{"nctId":"NCT03651726","phase":"PHASE2","title":"A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome","status":"UNKNOWN","sponsor":"Neurothera Labs Inc.","startDate":"2018-08","conditions":"Tourette Syndrome","enrollment":60},{"nctId":"NCT03398083","phase":"PHASE1","title":"Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-04","conditions":"Cannabis Use Disorder","enrollment":42},{"nctId":"NCT00682929","phase":"PHASE1, PHASE2","title":"Cannabis for Spasticity in Multiple Sclerosis","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2004-04-14","conditions":"Multiple Sclerosis","enrollment":41},{"nctId":"NCT00743119","phase":"PHASE2","title":"Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-06","conditions":"Pain Threshold, Mood","enrollment":34},{"nctId":"NCT03005119","phase":"PHASE2","title":"Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms","status":"UNKNOWN","sponsor":"PhytoTech Therapeutics, Ltd.","startDate":"2018-03-01","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT01394185","phase":"PHASE1, PHASE2","title":"Effects of Dronabinol (Oral THC) on Cannabis Use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-02","conditions":"Marijuana Smoking","enrollment":25},{"nctId":"NCT00438139","phase":"PHASE1","title":"Ph1 Marinol Interaction Study - Part 1 - 1","status":"TERMINATED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2007-03","conditions":"Marijuana Dependence","enrollment":6},{"nctId":"NCT00490269","phase":"PHASE1","title":"Ph1 Marinol Interaction Study - Part 2 - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2006-10","conditions":"Marijuana Dependence","enrollment":12},{"nctId":"NCT00079560","phase":"PHASE1, PHASE2","title":"Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-12","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02485158","phase":"NA","title":"Individual Differences in the Response to Drugs","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-07","conditions":"Healthy","enrollment":28},{"nctId":"NCT00943930","phase":"","title":"Marijuana Drug Discrimination and Self-Administration","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2009-04","conditions":"Marijuana Abuse","enrollment":29},{"nctId":"NCT01893424","phase":"PHASE1","title":"Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol)","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2013-08","conditions":"Pain","enrollment":12},{"nctId":"NCT02604992","phase":"NA","title":"Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2015-11","conditions":"Healthy","enrollment":54},{"nctId":"NCT02472847","phase":"PHASE4","title":"Cannabinoid Control of Fear Extinction Neural Circuits in Humans","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2012-05","conditions":"Healthy Participants","enrollment":85},{"nctId":"NCT00552604","phase":"PHASE3","title":"MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study","status":"TERMINATED","sponsor":"Institut fur Klinische Forschung, Germany","startDate":"2006-06","conditions":"Muscle Spasticity","enrollment":279},{"nctId":"NCT02094599","phase":"PHASE1","title":"A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2014-02","conditions":"Drug Abuse, Medication","enrollment":43},{"nctId":"NCT01740960","phase":"PHASE1","title":"Safety and Tolerability of Namisol in the Elderly","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-08","conditions":"Drug Safety","enrollment":12},{"nctId":"NCT00218504","phase":"","title":"Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2005-12","conditions":"Marijuana Abuse","enrollment":20},{"nctId":"NCT00959218","phase":"PHASE3","title":"Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis","status":"COMPLETED","sponsor":"Bionorica Research GmbH","startDate":"2007-06","conditions":"Central Neuropathic Pain in Multiple Sclerosis","enrollment":240},{"nctId":"NCT01149018","phase":"NA","title":"Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-06","conditions":"Fibromyalgia","enrollment":80},{"nctId":"NCT00642512","phase":"PHASE3","title":"Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2003-07","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":64},{"nctId":"NCT00642499","phase":"PHASE2","title":"Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2003-08","conditions":"Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BX-1"],"phase":"phase_3","status":"active","brandName":"Dronabinol in Oral Dosage Form","genericName":"Dronabinol in Oral Dosage Form","companyName":"Arbeitsgemeinschaft medikamentoese Tumortherapie","companyId":"arbeitsgemeinschaft-medikamentoese-tumortherapie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects. Used for Cancer-related anorexia and cachexia (Phase 3 investigation), Chemotherapy-induced nausea and vomiting (potential indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}